Full Press Release Details
MELBOURNE, June 26th 2017
In accordance with Listing Rule 3.14, the Company advises that
the Registered Office will change effective immediately.
The new address is detailed below:
| Registered Office |
| Level 3 62 Lygon Street Carlton Vic 3053 Australia Phone: +61 (0) 3 9824 5254 Postal address: P.O. Box 655 Carlton South Vic 053 |
The office is staffed during normal business hour (Monday to
Friday) from 08.30 to 17.00 AEST.
About Prana Biotechnology Limited
Prana Biotechnology was established to
commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated
in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent
international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts
General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.
For further information please visit the
Company's web site at www.pranabio.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act
of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends,"
"hopes," "anticipates," "believes," "could," "may," "evidences" and
"estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Such statements include, but are not limited to any statements relating to the Company's drug development program, including,
but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including,
but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development,
testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to,
PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products
coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but
not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company
makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements
are based on management's current expectations, but actual results may differ materially due to various factions including
those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking
statements as a prediction of actual future results.